New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia

Juliano Santos Souza, Monica Kayo, Jorge Henna Neto, Helio Elkis, Peter F Buckley

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Clozapine is the gold standard for treatment-refractory schizophrenia (TRS), but several patients only respond partially, despite adequate use. Furthermore, several issues might limit the use of clozapine, such hematological, metabolic or other disabling side effects. These issues prompted the investigation of clozapine augmentation strategies in partial responders to clozapine, as well as alternative strategies for TRS patients who do not tolerate the drug. Therefore, this chapter focuses on the novel and promising agents or techniques that have recently emerged as adjunctive treatments, such as lamotrigine, memantine and cognitive-behavioral therapy, for partial responders to clozapine. In terms of alternative strategies for patients with TRS, this review of the evidence showed modest results for risperidone and ziprasidone, while the use of high-dose olanzapine showed more consistent results, representing a viable alternative for patients with TRS who cannot use or tolerate clozapine. Nevertheless, such augmentation or alternative strategies still remain an open field of investigation.

Original languageEnglish (US)
Title of host publicationTherapy-Resistant Schizophrenia
PublisherS. Karger AG
Pages152-164
Number of pages13
Volume26
ISBN (Electronic)9783805595124
ISBN (Print)9783805595117
DOIs
StatePublished - Jul 29 2010

Fingerprint

Clozapine
Schizophrenia
olanzapine
Therapeutics
Memantine
Risperidone
Cognitive Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Psychology(all)

Cite this

Souza, J. S., Kayo, M., Neto, J. H., Elkis, H., & Buckley, P. F. (2010). New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia. In Therapy-Resistant Schizophrenia (Vol. 26, pp. 152-164). S. Karger AG. https://doi.org/10.1159/000319814

New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia. / Souza, Juliano Santos; Kayo, Monica; Neto, Jorge Henna; Elkis, Helio; Buckley, Peter F.

Therapy-Resistant Schizophrenia. Vol. 26 S. Karger AG, 2010. p. 152-164.

Research output: Chapter in Book/Report/Conference proceedingChapter

Souza, JS, Kayo, M, Neto, JH, Elkis, H & Buckley, PF 2010, New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia. in Therapy-Resistant Schizophrenia. vol. 26, S. Karger AG, pp. 152-164. https://doi.org/10.1159/000319814
Souza JS, Kayo M, Neto JH, Elkis H, Buckley PF. New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia. In Therapy-Resistant Schizophrenia. Vol. 26. S. Karger AG. 2010. p. 152-164 https://doi.org/10.1159/000319814
Souza, Juliano Santos ; Kayo, Monica ; Neto, Jorge Henna ; Elkis, Helio ; Buckley, Peter F. / New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia. Therapy-Resistant Schizophrenia. Vol. 26 S. Karger AG, 2010. pp. 152-164
@inbook{1138258ac70f4f5bb7b03f9be19a3f96,
title = "New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia",
abstract = "Clozapine is the gold standard for treatment-refractory schizophrenia (TRS), but several patients only respond partially, despite adequate use. Furthermore, several issues might limit the use of clozapine, such hematological, metabolic or other disabling side effects. These issues prompted the investigation of clozapine augmentation strategies in partial responders to clozapine, as well as alternative strategies for TRS patients who do not tolerate the drug. Therefore, this chapter focuses on the novel and promising agents or techniques that have recently emerged as adjunctive treatments, such as lamotrigine, memantine and cognitive-behavioral therapy, for partial responders to clozapine. In terms of alternative strategies for patients with TRS, this review of the evidence showed modest results for risperidone and ziprasidone, while the use of high-dose olanzapine showed more consistent results, representing a viable alternative for patients with TRS who cannot use or tolerate clozapine. Nevertheless, such augmentation or alternative strategies still remain an open field of investigation.",
author = "Souza, {Juliano Santos} and Monica Kayo and Neto, {Jorge Henna} and Helio Elkis and Buckley, {Peter F}",
year = "2010",
month = "7",
day = "29",
doi = "10.1159/000319814",
language = "English (US)",
isbn = "9783805595117",
volume = "26",
pages = "152--164",
booktitle = "Therapy-Resistant Schizophrenia",
publisher = "S. Karger AG",
address = "Switzerland",

}

TY - CHAP

T1 - New therapeutic strategies for resistance to clozapine and treatment-resistant schizophrenia

AU - Souza, Juliano Santos

AU - Kayo, Monica

AU - Neto, Jorge Henna

AU - Elkis, Helio

AU - Buckley, Peter F

PY - 2010/7/29

Y1 - 2010/7/29

N2 - Clozapine is the gold standard for treatment-refractory schizophrenia (TRS), but several patients only respond partially, despite adequate use. Furthermore, several issues might limit the use of clozapine, such hematological, metabolic or other disabling side effects. These issues prompted the investigation of clozapine augmentation strategies in partial responders to clozapine, as well as alternative strategies for TRS patients who do not tolerate the drug. Therefore, this chapter focuses on the novel and promising agents or techniques that have recently emerged as adjunctive treatments, such as lamotrigine, memantine and cognitive-behavioral therapy, for partial responders to clozapine. In terms of alternative strategies for patients with TRS, this review of the evidence showed modest results for risperidone and ziprasidone, while the use of high-dose olanzapine showed more consistent results, representing a viable alternative for patients with TRS who cannot use or tolerate clozapine. Nevertheless, such augmentation or alternative strategies still remain an open field of investigation.

AB - Clozapine is the gold standard for treatment-refractory schizophrenia (TRS), but several patients only respond partially, despite adequate use. Furthermore, several issues might limit the use of clozapine, such hematological, metabolic or other disabling side effects. These issues prompted the investigation of clozapine augmentation strategies in partial responders to clozapine, as well as alternative strategies for TRS patients who do not tolerate the drug. Therefore, this chapter focuses on the novel and promising agents or techniques that have recently emerged as adjunctive treatments, such as lamotrigine, memantine and cognitive-behavioral therapy, for partial responders to clozapine. In terms of alternative strategies for patients with TRS, this review of the evidence showed modest results for risperidone and ziprasidone, while the use of high-dose olanzapine showed more consistent results, representing a viable alternative for patients with TRS who cannot use or tolerate clozapine. Nevertheless, such augmentation or alternative strategies still remain an open field of investigation.

UR - http://www.scopus.com/inward/record.url?scp=84925970718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925970718&partnerID=8YFLogxK

U2 - 10.1159/000319814

DO - 10.1159/000319814

M3 - Chapter

AN - SCOPUS:84925970718

SN - 9783805595117

VL - 26

SP - 152

EP - 164

BT - Therapy-Resistant Schizophrenia

PB - S. Karger AG

ER -